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Analyses of vif HIV-1 virions derived from permissive
and nonpermissive cells revealed no differences in pro-
tein, RNA composition, or reverse transcriptase activitySummary
(Gaddis et al., 2003; Simon and Malim, 1996; von
Schwedler et al., 1993). Yet, vif HIV-1 virus derivedThe HIV-1 accessory protein Vif (virion infectivity fac-
from nonpermissive cells fails to complete a single cycletor) is required for the production of infectious virions
of replication. The virus appeared to initiate reverse tran-by CD4 lymphocytes. Vif facilitates particle infectivity
scription but failed to complete the synthesis of double-by blocking the inhibitory activity of APOBEC3G
stranded cDNA and failed to reach the proviral stage(CEM15), a virion-encapsidated cellular protein that
(Goncalves et al., 1996; Simon and Malim, 1996; vondeaminates minus-strand reverse transcript cytosines
Schwedler et al., 1993). Whether Vif is present in signifi-to uracils. We report that HIV-1 Vif forms a complex
cant quantity in virions is controversial (Camaur andwith human APOBEC3G that prevents its virion encap-
Trono, 1996; Dettenhofer and Yu, 1999; Fouchier et al.,sidation. HIV-1 Vif did not efficiently form a complex
1996; Khan et al., 2001; Liu et al., 1995; Simon et al.,with mouse APOBEC3G. Vif dramatically reduced the
1998). In somatic cell fusion experiments, heterokaryonsamount of human APOBEC3G encapsidated in HIV-1
formed by the fusion of permissive to nonpermissivevirions but did not prevent encapsidation of mouse
cells were found to be nonpermissive (Madani and Ka-or AGM APOBEC3G. As a result, these enzymes are
bat, 1998; Simon et al., 1998). This finding suggestedpotent inhibitors of wild-type HIV-1 replication. The
that nonpermissiveness is caused by an inhibitory fac-species-specificity of this interaction may play a role in
tor. Sheehy et al. (2002) identified the factor and termedrestricting HIV-1 infection to humans. Together these
it CEM15, a protein that is identical to apolipoproteinfindings suggest that therapeutic intervention that ei-
B mRNA editing enzyme, catalytic polypeptide-like 3Gther induced APOBEC3G or blocked its interaction
(APOBEC3G). Expression of APOBEC3G in permissivewith Vif could be clinically beneficial.
cells rendered them nonpermissive (Sheehy et al., 2002).
APOBEC3G is a member of a family of RNA editingIntroduction
enzymes (Jarmuz et al., 2002; Wedekind et al., 2003)
that deaminate specific cytosines to uracil in mRNA orThe genome of retroviruses that infect rodents and birds
DNA (Anant et al., 1995; Lau et al., 2001; Yang et al.,consist of gag, pol, and env genes that encode virion
2000). In humans, the family consists of APOBEC1, APO-structural proteins. The more complex genome of lentivi-
BEC2, APOBEC3A-G, and the activation-induced deam-ruses, which includes the simian (SIV) and human immu-
inase (AID) (Jarmuz et al., 2002; Muto et al., 2000; Wede-
nodeficiency viruses (HIV), encode six or seven addi-
kind et al., 2003). APOBEC2 and APOBEC3 have
tional proteins (Nef, Rev, Tat, Vif, Vpr, Vpu, and Vpx) that
features in common with APOBEC1, including a con-
serve regulatory or accessory roles in virus replication served intron/exon organization, tissue-specific expres-
(Emerman and Malim, 1998; Trono, 1995). Vif (virion in- sion, homodimerization, and zinc and RNA binding (Jar-
fectivity factor) is a 190–240 amino acid protein that muz et al., 2002). APOBEC1 and APOBEC3G also have
is encoded by all of the lentiviruses except for equine activity as DNA mutators that can trigger the cytosine
infectious anemia virus. The amino acid sequence of Vif deamination of target genes when expressed in E. coli
is relatively well conserved between HIV-1 strains, but (Harris et al., 2002). Recently, Lecossier et al. (Lecossier
is only 30% identical to Vif from rhesus macaque SIV et al., 2003) reported that in infected nonpermissive
(SIVmac) (Oberste and Gonda, 1992). SIVmac239 that cells, vif HIV-1 minus-strand reverse transcripts con-
is deficient in vif (vif), replicates to low titers in infected tained frequent G→A mutations, suggesting a role for
macaques and does not cause disease (Desrosiers et cytosine deamination.
al., 1998). We report here that HIV-1 Vif forms a complex with
vif HIV-1 does not replicate in primary T cells, macro- human APOBEC3G, preventing its encapsidation. HIV-1
phages or some CD4 transformed T cell lines (termed Vif did not form a complex with mouse APOBEC3G, and
“nonpermissive”). In contrast, several transformed T cell as a result, did not prevent its encapsidation. Conse-
lines (termed “permissive”) support the replication of quently, mouse APOBEC3G and APOBEC3Gs from AGM
vif HIV-1 (Gabuzda et al., 1992; Strebel et al., 1987; and rhesus macaque, were potent inhibitors of HIV-1
replication that were resistant to HIV-1 Vif. These find-
ings provide a molecular mechanism for Vif function*Correspondence: landau@salk.edu
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and have implications regarding the restriction of HIV-1 antiviral property of APOBEC3G is conserved by the
mouse protein but that the ability to functionally interactinfection to humans and the host factors that influence
with Vif is species-restricted, probably reflecting in vivodisease progression in infected individuals.
selective pressure on Vif to adapt to the human enzyme.
Most of the other rodent APOBEC3Gs shared theResults
property of Vif-resistant inhibition of HIV-1 infectivity
(Figure 1B) including those from L1.2, CHO, and 3T3. InRodent APOBEC3Gs Prevent Wild-Type
contrast, EL4, Rat2, and MDTF APOBEC3G were inac-HIV-1 Replication
tive, raising the possibility of strain and species differ-Lentiviruses such as HIV-1 and SIV require Vif for replica-
ences in antiviral function. EL4 APOBEC3G was identicaltion in primary cells but simpler retroviruses, such as
to C57BL/6 APOBEC3G with the exception of a changemurine leukemia virus (MLV), do not. The reason for this
of S281G in the second Zn2 coordination domain, sug-difference is not known. One possible explanation would
gesting the importance of catalysis in the antiviral phe-be the absence of a functional APOBEC3G ortholog in
notype. Each of the APOBEC3Gs contained a C-terminalthe host species. The Mus musculus genome contains
HA epitope tag. The HA tag did not interfere with functiona single gene with similarity to human APOBEC3G (for
and allowed detection of the proteins in the cell lysatessimplicity, provisionally termed in this study “mouse
(Figure 1C).APOBEC3G”). The predicted protein differs from human
To determine whether the mouse APOBEC3G geneAPOBEC3G by 70% but conserves the two Zn2 coordi-
was expressed in vivo, the abundance of APOBEC familynation domains that are characteristic of cytosine deam-
member mRNAs was measured by real-time quantitativeinases (Wedekind et al., 2003). To determine whether
PCR (Figure 1D). APOBEC3G mRNA was most abundantrodent APOBEC proteins retain the antiviral activity of
in splenic lymphocytes. APOBEC3G mRNA was alsohuman APOBEC3G, rodent APOBEC1, APOBEC2, and
detected in lymph node lymphocytes and lung, a tissueAPOBEC3G cDNAs were derived from C57BL/6 spleno-
rich in macrophages. The mRNA was not detected incytes. In addition, APOBEC3G cDNAs were cloned from
muscle, kidney, heart, brain, liver, or thymus and itsNIH-3T3, EL4 thymoma cells, L1.2 B lymphoma cells,
pattern of expression differed from that of APOBEC1Chinese hamster ovary cells (CHO), Mus dunni tail fibro-
and APOBEC2. The absence of the mRNA in thymus,blast (MDTF), and Rat2 rat fibroblasts (Sequences are
which is rich in immature T cells, suggested that theshown in the Supplemental Data available at http://
gene is not activated until late in T cell development.www.cell.com/cgi/content/full/114/1/21/DC1). A hem-
Primers that distinguished the full-length and exonagglutinin (HA) epitope tag was linked to the C terminus
V-deleted mRNA detected only the latter in all of theof each cDNA and these were transferred to plasmid
tissues (data not shown). This form was therefore used(pcDNA3.1) and retroviral (pBABE-neo; Morgenstern and
in the subsequent experiments. Taken together, the find-Land, 1990) expression vectors. Nearly all of the rodent
ings suggested that APOBEC3G is mainly expressed inAPOBEC3G cDNAs were derived from an alternatively
lymphocytes and monocytes of the mouse, cell-typesspliced mRNA that lacked exon V. The deletion removed
that are targeted by retroviruses.
the 99 nucleotides that encode amino acids 199 to 232.
To quantitatively compare the activities of mouse and
Only a single full-length cDNA, which was derived from
human APOBEC3G, wild-type, and vif reporter viruses
NIH 3T3, was found.
were prepared in cells expressing a range of APOBEC3G
To measure Vif and APOBEC3G function, we devel- concentrations (Figure 2). Human APOBEC3G caused a
oped an assay based on the single-cycle luciferase re- relatively small, 3-fold decrease in infectivity of the wild-
porter virus pNL-LucRE(Connor et al., 1995; Deng et type virus and a more pronounced 80-fold decrease
al., 1996). In the assay, wild-type and vif luciferase re- in infectivity of the vif virus. The mildly inhibitory effect
porter viruses were produced by cotransfection of 293T of human APOBEC3G at the highest concentrations on
cells with pNL-LucREor pNL-LucREvif, APOBEC3G wild-type virus suggested that Vif could become limiting
expression vector and JR.FL envelope glycoprotein or under some conditions. Mouse APOBEC3G reduced the
VSV-G expression vector to pseudotype the particles infectivity of wild-type andvif viruses to a similar extent
(Connor et al., 1995; Deng et al., 1996). HOS.CD4.R5 over the range of concentrations. The similarity of the
cells were then infected with equivalent amounts of each responsiveness of thevif virus to the mouse and human
virus (Deng et al., 1996). Infectivity of the viruses was enzymes confirmed that the two proteins were of similar
determined by quantitation of intracellular luciferase ac- potency but that the mouse enzyme was resistant to
tivity three days later. The ability of the assay to measure HIV-1 Vif. Immunoblot quantitation of the amount of
APOBEC3G function was demonstrated by the dramati- mouse and human APOBEC3G expressed in the cells
cally reduced infectivity of vif reporter virus that had demonstrated that the resistance of mouse APOBEC3G
been produced in the presence of human APOBEC3G to HIV-1 Vif was not due to overexpression of the mouse
(Figure 1A). Mouse APOBEC3G was also active against enzyme (Figure 2). Lower molecular weight bands
vif HIV-1. Unexpectedly, the mouse enzyme was that appeared to be degradation products of human
equally active against the wild-type virus, reducing APOBEC3G were faintly visible on immunoblots on ly-
its infectivity 150-fold in some experiments. Mouse sates of cells in which Vif had been expressed.
APOBEC1 and APOBEC2 were inactive (Figure 1A) as To determine whether mouse APOBEC3G would
were human APOBEC3A-F (not shown). The full-length protect cells from productive HIV-1 replication as a re-
mouse APOBEC3G (NIH-3T3 cDNA) and the more com- sult of its Vif-resistant phenotype, HOS.CD4.X4 cells
mon exon V-deleted (e.g., C57BL/6 cDNA) were similarly were prepared that stably produced human or mouse
APOBEC3G and then challenged with wild-type andvifactive (Figure 1B). These findings demonstrated that the
Species Specificity of APOBEC3G-Vif Interaction
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Figure 1. Rodent APOBEC3G Inhibits Wild-
Type and vif HIV-1 and Is Expressed in
Lymphoid Tissues
(A) Wild-type and vif HIV-1 luciferase re-
porter viruses were produced in 293T cells in
the presence or absence of human APO-
BEC3G, or mouse APOBEC1, APOBEC2,
or APOBEC3G. cDNAs were derived from
C57BL/6 spleen. Infectivity of the viruses on
HOS cells was determined three days postin-
fection by quantitation of intracellular lucifer-
ase activity.
(B) WT and vif HIV-1 luciferase reporter vi-
ruses were produced in the presence of the
indicated rodent APOBEC3G.
(C) 293T cells were transfected with human
or mouse APOBEC3G-HA expression vector
and the protein expressed was detected on
immunoblots probed with anti-HA mono-
clonal antibody (mAb).
(D) APOBEC1, APOBEC2, and APOBEC3G
mRNA was quantitated in mouse tissues by
real-time PCR. The results are normalized to
GAPDH.
NL4-3 HIV-1. Control HOS.CD4.X4 cells were suscepti- showed that clones 1 and 3 were nonpermissive (sup-
ported replication of wild-type but not vif virus); clonesble to both viruses which spread rapidly in the cul-
ture and killed the cells in 5–7 days. Six independent 5 and 6 were semipermissive and, interestingly, clones
2 and 4 were resistant to wild-type and vif replicationHOS.CD4.X4 cell clones that expressed a similar amount
of mouse APOBEC3G were tested (Figure 3A). None (Figure 3C). Thus, moderate levels of human APOBEC3G
can limit wild-type HIV-1 replication, a finding that hasof the cell lines supported detectable vif or wild-type
NL4-3 replication (a representative clone is shown in potential clinical relevance.
Figure 3B). HOS.CD4.X4 cell clones were found to ex-
press variable amounts of human APOBEC3G (Figure Macaque and AGM APOBEC3G Block
Wild-Type HIV-1 Infectivity3A). Clones 2 and 4 expressed the largest amount of
human APOBEC3G while clones 1, 3, 5, and 6 expressed HIV-1 does not replicate productively in nonhuman pri-
mates with the exception of the chimpanzee. The Vif-2–5 fold less. Measurement of virus replication kinetics
Figure 2. Inhibition by Mouse APOBEC3G Is Vif-Resistant
Wild-type and vif luciferase reporter viruses pseudotyped by JR.FL glycoprotein were produced in 293T cells transfected with decreasing
amounts of human (hu-) or mouse (mu-) APOBEC3G-HA expression vector. The amount of expression vector plasmid transfected is shown
in g on the X-axis. Infectivity of the viruses was determined on HOS.CD4.R5 cells by intracellular luciferase quantitation. Below each histogram
an immunoblot probed with anti-HA mAb of the proteins present in the cell lysates is shown. The lower molecular weight proteins in the upper
left panel are putative degradation products of human APOBEC3G.
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Figure 3. Virus Replication Kinetics in Cells
Expressing Mouse or Human APOBEC3G
(A) Human and mouse APOBEC3G expressed
by HOS.CD4.X4 cell clones derived by retro
viral vector transduction was detected on im-
munoblots probed with anti-HA mAb. The pa-
rental cells (M) lack endogenous APOBEC3G.
(B) HOS.CD4.X4 and mouse APOBEC3G ex-
pressing cell lines were infected with wild-
type and vif NL4-3 HIV-1. Supernatant p24
was measured over two weeks. Representa-
tive data for one clone is shown.
(C) Individual cell clones that stably ex-
pressed different amounts of human APO-
BEC3G were infected as in B.
resistant inhibition of HIV-1 by mouse APOBEC3G raised quency among the four classes of virions which each
differed by 0.01% from the parental NL4-3 (not shown).the question of whether this phenomenon could be a
more general property of nonhuman APOBEC3G and In contrast, sequences of a 100 bp region 5 to the
PBS of viral cDNA from newly infected cells showedcould account for species-specific restrictions to HIV-1.
To determine whether simian APOBEC3G could restrict pronounced differences in mutation frequency that were
APOBEC3G and Vif-dependent (Figure 5A). ReverseHIV-1, AGM, rhesus macaque and chimpanzee APO-
BEC3G were cloned, sequenced, and tested against transcripts that were synthesized by wild-type and vif
virus produced in the absence of APOBEC3G were rarelywild-type andvif HIV-1, SIVagm, and SIVmac luciferase
reporter viruses. Sequences of primate, human, and mutated (0.064%–0.027%). The mutation frequency was
slightly higher for wild-type virus produced in the pres-mouse APOBEC3G are aligned in Figure 4A. Chimpan-
zee APOBEC3G was most similar to human, differing ence of APOBEC3G (0.6%), consistent with incomplete
protection by Vif. The mutation rate was higher for vifin amino acid sequence by 5%. AGM and macaque
APOBEC3G were more divergent, differing from human virus produced in the presence of human APOBEC3G
(1.23%) and for wild-type (1.53%) and vif (0.92%) vi-by 23% and 25%, respectively, but were 88% identical
to one another. The reporter virus analysis showed that ruses produced in the presence of mouse APOBEC3G.
Two hot spots for mutation by the mouse and humanthe three primate APOBEC3Gs were active against vif
HIV-1 (Figure 4B). AGM and macaque APOBEC3G, like enzymes contained the sequence TGG. Of the nucleo-
tides changed in the presence of human or mouse APO-the mouse enzyme, were resistant to HIV-1 Vif, blocking
wild-type HIV-1. Only the chimpanzee APOBEC3G was BEC3G, 78% and 84% were G→A, respectively. Such
changes are consistent with cytosine deamination tosensitive to HIV-1 Vif. Each of the APOBEC3Gs was
active against vif SIVmac and was sensitive to SIVmac uracil in the viral minus-strand cDNA that is subse-
quently copied as A in the plus strand.Vif. AGM and macaque APOBEC3G were sensitive to
SIVagm Vif. Interestingly, human and chimpanzee APO-
BEC3G were resistant to AGM Vif. Thus, these enzymes APOBEC3G Deamination Blocks Integration
are expected to block SIVagm but not SIVmac infection by Inducing Degradation of Newly
of humans and chimpanzees. Synthesized Reverse Transcripts
We next investigated the effect of cytosine deamination
on the fate of the viral reverse transcripts. Three mecha-Mouse APOBEC3G Induces G→A Changes
in Minus-Strand cDNA Similar to Those nisms could account for the block to replication caused
by uracil in the viral cDNA: (1) uracil-containing minus-Induced by Human APOBEC3G
Nucleotide sequences of the viral genomic RNA in wild- strand cDNA might be an inefficient template for plus-
strand synthesis; (2) full-length cDNA could be gener-type and vif viruses formed in the presence or absence
of human APOBEC3G were determined. Sequences ated but then degraded by DNA repair enzymes such
as uracil DNA glycosylase and apurinic endonucleasewere determined of a 200 bp region that included the
primer binding site (PBS) and 5-LTR of 12 clones from (Krokan et al., 2002); and (3) double-stranded viral cDNA
could integrate to form a provirus but then fail to encodeeach virus. There was no difference in mutation fre-
Species Specificity of APOBEC3G-Vif Interaction
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Figure 4. Simian APOBEC3Gs Are Vif-Resistant Inhibitors of HIV-1
(A) Aligned sequences of primate and mouse APOBEC3G are shown. The Zn2 coordination domains are boxed. Arrows indicate conserved
cysteine and histidine residues.
(B) Wild-type and vif HIV-1, SIVmac, and SIVagm luciferase reporter viruses were prepared as VSV-G pseudotypes in the presence of human,
AGM, macaque, chimpanzee, or mouse APOBEC3G. The viruses were produced in 293T cells transfected with equal quantities of reporter
virus, APOBEC3G expression vector and pcVSV-G plasmids. Infectivity of the viruses normalized for capsid (CA) was measured on HOS.CD4
cells.
functional viral proteins because of frequent inactivating Vif Binds to APOBEC3G Blocking Encapsidation
of Human but Not Mouse or AGM APOBEC3Gmutations. To distinguish these possibilities, viral cDNA
APOBEC3G is encapsidated in vif HIV-1 virions (Sheehysynthesis was analyzed by quantitative real-time PCR
et al., 2002) and upon infection, deaminates newly synthe-in a single cycle of replication using primers specific for
sized viral reverse transcripts. In light of the species-early reverse transcripts, late reverse transcripts, and
specificity of the Vif:APOBEC3G interaction, we hy-integrated proviruses (Figure 5B). Early reverse tran-
pothesized that Vif binds to APOBEC3G, preventing thescripts peaked at 10 hr and then decreased in abun-
enzyme from causing cytosine deamination. We firstdance over time and this was not influenced by APO-
tested whether Vif would influence the amount of APO-BEC3G. Late reverse transcripts peaked between 9–12
BEC3G encapsidated into virions. Wild-type and vifhr and were similar for each of the viruses until 24 hr at
virions produced in the presence or absence of human,which thevif/APOBEC3G virus decreased to undetect-
mouse, or AGM APOBEC3G were pelleted through su-able levels. Although degradation of the cDNA occurred
crose. The amount of encapsidated APOBEC3G was
for all of the viruses, consistent with Butler et al. (2001),
quantitated on immunoblots (Figures 6A and 6B). Human
the decrease was most pronounced for the vif-defec- APOBEC3G was detected as an intense band in vif
tive virus. Quantitation of integrated proviruses revealed virions, but was reduced 140-fold in wild-type virions
a more pronounced defect. The vif defective viruses (Figure 6A). In contrast, mouse and AGM APOBEC3G
generated about 7-fold fewer proviruses than the active were present in virions regardless of whether Vif was
viruses (Figure 5B). Taken together, these data suggested expressed. In fact, wild-type virions reproducibly con-
that deamination of the minus-strands by APOBEC3G dur- tained 2–3-fold more mouse and AGM APOBEC3G than
ing reverse transcription does not interfere with comple- vif particles (Figure 6A). In cell lysates, Vif caused a
tion of cDNA synthesis but that the presence of uracil modest 3-fold reduction in human but not mouse or
results in degradation of the molecules prior to inte- AGM APOBEC3G (Figure 6B).
The most straightforward explanation of these resultsgration.
Cell
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Figure 5. Mouse and Human APOBEC3G Induce Cytosine Deamination of Minus-Strand Reverse Transcripts that Results in Degradation of
the Viral DNA
(A) HOS.CD4.X4 cells were infected with DNase-treated virions produced by transfected 293T cells. Cellular DNA was prepared 12 hr
postinfection and a 140 base pair sequence containing the PBS, U5, and R was amplified, cloned, and sequenced. The parental NL4-3
sequence is shown below. The height of the bars corresponds to the percentage of clones in which the underlying nucleotide was changed.
The color of the bar indicates the nucleotide that was introduced. “n” indicates the number of independent clones sequenced.
(B) HOS cells lacking receptors were infected in triplicate with VSV-G pseudotyped NL4-3 or vif NL4-3 produced in transfected 293T cells
in the presence or absence of human APOBEC3G. Cultures were lysed at the specified times postinfection and DNA was prepared. Newly
synthesized cDNA was measured by quantitative real-time PCR with primers specific for early, late reverse transcripts or integrated proviruses
(Butler et al., 2001). The results are representative of four independent repetitions of the experiment.
was that Vif physically bound to APOBEC3G, preventing Because MLV does not require Vif for its replication,
we expected that it would not encapsidate APOBEC3G.its encapsidation. To detect a complex containing the
two proteins, APOBEC3G-HA was immunoprecipitated Surprisingly, MLV virions were found to contain large
quantities of human, mouse, and AGM APOBEC3G (Figurefrom 293T cells cotransfected with wild-type or vif NL4-3
and lysed in mild detergent. Coimmunoprecipitated Vif 6A). In light of this finding, we tested the effect of human
and mouse APOBEC3G on MLV infectivity. MDTF andwas then detected on immunoblots probed with anti-
Vif serum (Figure 6C). This analysis detected a complex HOS cells were infected with single-cycle, MLV-EGFP at
an MOI that would be maximally sensitive to changesof HIV-1 Vif with human but not mouse APOBEC3G.
The detection of faint degradation products of in infectivity (Figure 6E). Encapsidated APOBEC3G was
detected on immunoblots (Figure 6E, right). Mouse andAPOBEC3G in Figure 2 and the modest decrease in
lysate human APOBEC3G caused by Vif suggested that human APOBEC3G caused a minimal reduction (2-
fold) in the number of EFGP cells. Thus, MLV is rela-Vif might exclude human APOBEC3G by causing its
rapid degradation. To test this possibility, the half-life tively resistant to APOBEC3G, regardless of APOBEC3G
in the virions.of APOBEC3G was measured by pulse-chase metabolic
labeling (Figure 6D). Vif was found to cause a 4.6-fold
decrease in the amount of APOBEC3G initially synthe- Discussion
sized, but did not affect the half-life of the enzyme. Thus,
Vif does not primarily exclude APOBEC3G from virions We report here that the antiviral activity of APOBEC3G is
maintained across diverse species in spite of extensiveby a degradative mechanism. The effects of Vif on
APOBEC3G levels are likely to be secondary effects. amino acid sequence divergence and regardless of
Species Specificity of APOBEC3G-Vif Interaction
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Figure 6. HIV-1 Vif Prevents Virion Encapsidation of Human but Not Mouse or AGM APOBEC3G and Binds Specifically to Human APOBEC3G
(A) Wild-type and vif NL4-3 HIV-1 virions and MLV virions prepared in 293T cells cotransfected with the indicated APOBEC3G expression
vector were pelleted through 20% sucrose. The virions, normalized for CA, and cell lysates, normalized for protein, were analyzed on
immunoblots probed with anti-HA mAb. The MLV virions were prepared by transfection of 293T cells with pMX-EGFP (Onishi et al., 1996),
pHIT60, pcVSV-G, and the indicated APOBEC3G expression vector. The results are representative of three independent experiments. Viral
DNA was omitted in “mock”. The presence () or absence () of APOBEC3G is indicated above each lane.
(B) A repetition of the experiment in (A) was quantitated and the results for the human APOBEC3G are shown as the average of triplicates.
(C) 293T cells were cotransfected with wild-type and vif pNL4-3 and human or mouse APOBEC3G-HA expression vector. Lysates were
immunoprecipitated with anti-HA mAb or with anti-Vif. Precipitated Vif was detected on immunoblots probed with anti-Vif serum.
(D) The half-life of human APOBEC3G in the presence or absence of HIV-1 Vif was measured by pulse-chase metabolic labeling. The bands
were quantitated and the cpm at t 0 was normalized to 100 (shown on the right). At t 0 wild-type was 60,000 cpm and vif was 13,000 cpm.
(E) HOS.CD4 and MDTF were infected with MLV-EGFP. The infected cells were quantitated by FACS and the percent EGFP cells is indicated
in the upper right of each quadrant. The data shown are representative of three independent repetitions of the experiment. Infection with 10-
fold more virus resulted in 96% EGFP cells and similar results (not shown). An immunoblot to quantitate the APOBEC3G content of the
MLV virions is shown at right.
whether lentiviruses infect the species. Mouse, ma- Our findings suggest a model for APOBEC3G and Vif
function in HIV-1 replication (Figure 7). In nonpermissivecaque, and AGM APOBEC3Gs were potent inhibitors,
not only of vif HIV-1, but also of wild-type virus. The cells infected with vif HIV-1, APOBEC3G is packaged
into the virions during virus assembly. When APOBEC3G-nonhomologous APOBEC3Gs, like the human enzyme,
were virion encapsidated and induced cytosine deami- containing vif virions infect a new cell, minus-strand
cDNA reverse transcription is initiated and the encapsi-nation to uracil of the viral minus-strand reverse tran-
scripts. Vif efficiently prevented human APOBEC3G dated APOBEC3G deaminates cytosines in the newly
synthesized DNA. The incorporated uracil does not in-from becoming virion-encapsidated but failed to prevent
the encapsidation of nonhomologous APOBEC3G, which terfere with further reverse transcription but destabilizes
the DNA, causing it to degrade before integration. In awas found in virions at high levels regardless of Vif.
HIV-1 Vif formed a complex with human but not mouse nonpermissive cell infected with wild-type virus, Vif binds
to APOBEC3G, blocking its encapsidation, and pre-APOBEC3G. Thus, Vif-resistant inhibition is caused by
a failure of HIV-1 Vif to interact with nonhomologous venting the subsequent cytosine deamination. In cells that
express a nonhomologous APOBEC3G, Vif fails to blockAPOBEC3G to prevent its encapsidation.
Cell
28
Figure 7. Proposed Model for APOBEC3G
and Vif function
In nonpermissive cells infected with vif
HIV-1, the assembling virion encapsidates
APOBEC3G. The encapsidated APOBEC3G
does not alter the viral genomic RNA or pro-
duction of virions. Upon infection of a new
cell, minus-strand cytosines are deaminated
to uracil at TGG sequences during reverse
transcription. The uracil-containing DNA is
degraded, causing a block to integration. In
cells infected with wild-type virus, Vif binds
to APOBEC3G preventing its encapsidation.
HIV-1 Vif does not bind tightly with mouse or
simian APOBEC3G, and thus fails to prevent
their encapsidation.
encapsidation of the deaminase. Minus-strand cyto- masking a domain on APOBEC3G that mediates the
interaction with the assembling virion. Alternatively, Vifsines are deaminated resulting in uracil-containing re-
verse transcripts that are poor substrates for integration. could direct APOBEC3G away from sites of virus as-
sembly.Some features of the model are supported by the data
but not fully established. Efficient completion of reverse Vif formed a complex with human but not mouse
APOBEC3G. This suggested that the species-specificitytranscription of the uracil-containing minus-strand cDNA
was suggested by the real-time PCR measurements and of Vif:APOBEC3G complex formation accounts for the fail-
ure of HIV-1 Vif to exclude nonhomologous APOBEC3Gis consistent with findings of Gaddis et al. (2003). Degra-
dation of the uracil-containing viral DNA prior to integra- from virions. This specificity probably originated both
from evolutionary selection for Vif to interact with thetion was supported by the decreased abundance of
completed cDNA of vif virus at the late time point and homologous APOBEC3G and the sequence divergence
of APOBEC3G in the various species. Interestingly, vifby the 7-fold decrease in the number of integrated provi-
ruses. Cellular DNA repair enzymes such as uracil DNA virions encapsidated more mouse and AGM APOBEC3G
than wild-type virions. Perhaps this is because Vif ex-glycosylase and apurinic endonuclease could play a
role in degradation of the uracil-containing viral cDNA cludes other, unidentified cellular proteins from virions,
allowing for more efficient encapsidation of nonhomolo-(Krokan et al., 2002). APOBEC3G did not completely
prevent integration of the viral cDNA. However, the pro- gous APOBEC3G.
The predominance of G→A sequence changes in theviruses that escaped degradation are likely to be heavily
mutated and not competent for further replication. reverse transcripts was consistent with the recent find-
ings of Lecossier et al. (2003), Harris et al. (2003),Taken together, the data suggest that there is a small
effect on preintegrative DNA, a larger effect on the num- Mangeat et al. (2003), and Zhang et al. (2003) and is
consistent with preferential deamination of the minus-ber of proviruses that integrate and a much larger effect
on functional capacity of the integrated viral DNA. G→A strand cDNA. The preference for minus-strand degrada-
tion could be caused by a requirement to deaminatechanges are expected to introduce frequent transla-
tional stop codons in the open reading frames of the single-stranded DNA generated by the RNaseH activity
of reverse transcriptase. By analogy, AID deaminatesviral genes.
The coimmunoprecipitation findings demonstrated cytosine in the single-stranded cellular DNA that forms
at R loops in the switch regions adjacent to immunoglob-that Vif forms a complex with APOBEC3G. However, the
mechanism by which Vif prevents APOBEC3G encapsi- ulin isotype genes (Honjo et al., 2002).
It is not clear whether APOBEC3G evolved in mam-dation is not clear. The presence of low molecular weight
APOBEC3G fragments in the presence of Vif and a mod- mals to counteract retroviral replication or whether the
antiviral activity of APOBEC3G is an inadvertent conse-est reduction in cellular APOBEC3G were suggestive of
Vif-induced degradation. However, pulse-chase analy- quence of its physiological function. Rodents are not
known to be infected by lentiviruses and thus were undersis showed that Vif did not affect the half-life of human
APOBEC3G. Its only effect was a modest (4.6-fold) de- no selective pressure to evolve an antilentiviral activity
or to maintain this activity through evolution, yet theircrease in APOBEC3G synthesis that could have been
caused by Vif binding to nascent APOBEC3G, interfering genomes encode an APOBEC3G that blocks lentivirus
replication. It is possible that APOBEC3G is incorpo-with the completion of its synthesis. Vif-induced degra-
dation of APOBEC3G, although induced to a small ex- rated into virions because it has affinity for a virion com-
ponent or because it localizes to cellular sites of virustent, did not appear to be the primary mechanism by
which it blocked APOBEC3G encapsidation. One possi- assembly. But whether the property of virion encapsida-
tion was fortuitous or whether it was evolutionarily se-bility is that Vif prevents APOBEC3G encapsidation by
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EcoRI and XhoI restriction sites. Mouse APOBEC1 and APOBEC2lected for its protective quality, remains to be deter-
cDNAs were amplified with primers containing BamHI and XhoI restric-mined.
tion sites. Chimpanzee, Rhesus macaque, and AGM APOBEC3G wereOur findings differ significantly from those recently
amplified with primers containing EcoRI and XhoI sites. Antisense prim-
reported by Harris et al. (2003) who found Vif-sensitive ers encoded the influenza hemagglutinin (HA) sequence YPYDVPDYA.
inhibition of MLV by human APOBEC3G. The reason for Amplicons were cleaved at the restriction sites and ligated to simi-
larly cleaved pcDNA3.1 (Invitrogen) or pBABE-neo (Morgensternthis difference is unclear but could be related to differ-
and Land, 1990). See Supplemental Data (available at http://www.ences in the amount of APOBEC3G encapsidated into
cell.com/cgi/content/full/114/1/21/DC1) for oligonucleotide and ro-the virions or to differences in the packaged RNA ge-
dent APOBEC3G cDNA sequences.nomes used in the two studies. Nevertheless, it is clear
that MLV has a means of replicating in the presence of
HIV-1, SIV, and MLV Plasmid Constructs
APOBEC3G, which as we demonstrated, is enzymati- Replication-competent vif HIV-1 (pNL4-3-vif) was generated by
cally active, expressed in mouse leukocytes, and encap- introducing stop codons near the 5 end of vif at nt 4472 and nt
sidated into MLV virions. A scan for the APOBEC3G 4474 by overlapping PCR. A 5 vif fragment was amplified with the
primers gag671Xho (5-CGA CGC TCG AGG CCA GAG GAG ATCtarget sequence TGG in MLV shows that these are abun-
TCT C) and 3Vif (5-CCT TGA AAT ATA CTA TTA TAC TAA TCTdant in the virus genome and have not been removed
TTT CC) and a 3 fragment was generated with primers 5Vifby evolutionary selective pressure. Thus, MLV has a
(5-GGA AAA GAT TAG TAT AAT AGT ATA TTT CAA GG) and 3-vpr
yet undetermined mechanism of resisting APOBEC3G- (5-CGC GGA TCC TCC TGG ATG CTT CCA). The 5 and 3 amplicons
mediated deamination. were mixed, denatured, and amplified with the external primers
The species-specificity of the Vif:APOBEC3G interac- gag671Xho and 3-vpr. The amplicon was cloned into the SphI (nt
1447) and EcoRI (nt 5743) sites of pNL4-3. To generate viftion probably plays a role in restricting HIV-1 infection
SIVmac239, a 5 vif fragment was amplified from pSIVmac239 withto humans. The Vif-resistant inhibitory activity of rhesus
primers F-SIV5330 (5-GCA TGA ATT TTA AAA GAA GGG GAG G-3)macaque and AGM APOBEC3G would prevent replica-
and R-Stop7 (5-GGG CAC ATA GCA AAC CTT TTG CAA GTT TTA
tion of HIV-1 in these species. Such restrictions impose TAT TTC AGA TAT TTT ATG AG) and a 3 fragment was amplified
an obstacle to the development of animal models for with the primers F-Stop7 (5-CTC ATA AAA TAT CTG AAA TAT
AIDS. Development of an animal model in which HIV-1 AAA ACT GAC AAA AGG TTT GCT ATG TGC CC) and R-SIV6300
(5-GCC TTT TGT ATT AAA CAC AAG TAT CTG). The two ampliconsinfects nonhuman primates or rodents will require re-
were mixed, denatured, and amplified with the external primersmoval of the APOBEC3G block. Transgenic rats and rat
F-SIV5330 and R-SIV6300. The amplicon was then cloned into thecells are more susceptible than mice to HIV-1 infection
unique PacI (nt 5386) and BstBI (nt 6132) sites of pSIVmac239. Virus
(Keppler et al., 2001, 2002), a finding that may be related stocks were prepared by transfection of 293T cells.
to the relatively weak antiviral activity of rat APOBEC3G. Single-cycle vif HIV-1 luciferase reporter virus pNL-Luc-ER-
In addition, some strains of mice may be more permis- vif was generated by T4 polymerase fill-in of the NdeI site (nt 4501)
near the 5 end of vif in pNL-Luc-ER (Connor et al., 1995; Dengsive than others to HIV-1 due to differences in the activity
et al., 1996). SIVmac luciferase reporter virus pSIV-Luc-ERvifof their APOBEC3G.
was generated by replacing the vif-containing PacI-BstBI fragmentThe finding that a moderate amount of human
of pSIV-HSA with that from pSIVmac239-vif. The HSA gene was
APOBEC3G also imposes a degree of Vif-resistant inhi- removed by cleaving with NotI and XhoI and replaced with the firefly
bition of HIV-1 replication has potential implications for luciferase gene. SIVagm luciferase reporter virus was generated by
AIDS progression. In vivo, some cell types may express fill-in of the AgeI site (nt 5337) near the 5 end of vif in SIVagm TAN-1
(Soares et al., 1997). The luciferase gene was inserted in-frame withquantities of APOBEC3G sufficient to limit wild-type vi-
the nef initiation codon at the BsiWI site (nt 8814). Virus stocks wererus replication. In addition, APOBEC3G, like the related
produced as JR.FL or VSV-G pseudotypes by cotransfection of 293TAID, is likely to be regulated by cellular activation signals
using Lipofectamine 2000 (Invitrogen) and were quantitated by p24
and these could increase expression to limiting levels. or p27 ELISA.
Furthermore, polymorphisms analogous to those of the To generate single-cycle MLV encoding EGFP (MLV-EGFP), EGFP
CCR5 promoter could affect APOBEC3G expression was cloned into pMX (Onishi et al., 1996) at the EcoRI-NotI sites.
VSV-G pseudotyped MLV-EGFP was prepared by cotransfection ofand contribute to differential rates of disease progres-
293T cells with pHIT-60 Gag/Pol expression vector (Soneoka et al.,sion. Limiting levels of APOBEC3G in vivo are suggested
1995) and pcVSV-G and normalized by quantitation on immunoblotsby previous reports of G→A hypermutation in patient-
probed with anti-MLV serum.
derived HIV-1 isolates (Borman et al., 1995; Vartanian et
al., 1991, 1994, 2002). If this is the case, then therapeutic Real-Time PCR Quantitation of APOBEC3G mRNA
intervention that either induced APOBEC3G or blocked Total cellular RNA was prepared using Triazol (Gibco/BRL) and
its interaction with Vif could be clinically beneficial. treated with 20 U RNase-free DNase for 1 hr at 37	. Oligo-dT primed
cDNA was synthesized with Superscript II reverse transcriptase us-
ing 500 ng RNA template and amplified in an Applied BiosystemsExperimental Procedures
Prism 7700. Amplification was monitored by SYBR green fluores-
cence. Standard curves were derived by serial dilution of pc-mu-Cloning of Rodent, Human, and Primate APOBECs
APOBEC3G and pcGAPDH. Mouse APOBEC3G was amplified withRodent and human RNA was prepared from C57BL/6 mouse spleen
F-mu-CEM15.309 and R-mu-CEM15.359. RNAs were normalized byand thymus, NIH 3T3, Mus dunni tail fibroblasts (MDTF), CHO (Ameri-
amplification of GAPDH with specific primers.can Tissue Culture Collection CCL-61) (Puck, 1958), Rat2, EL4 (Ralph
and Nakoinz, 1973), L1-2 (Jutila et al., 1994), and CEMSS (Foley
et al., 1965; Nara and Fischinger, 1988). Chimpanzee (CPZ, Pan Assays for Vif/APOBEC3G Function and Encapsidation
Reporter viruses were prepared in the presence or absence ofTroglodytes), rhesus macaque (MAC, Macaca mulatta), and African
green monkey (AGM, Chlorocebus aethiops) RNA was prepared APOBEC3G by cotransfection of 293T with 2g APOBEC3G expres-
sion vector or control empty vector; 2 g wild-type or vif reporterfrom PHA-activated PBMC. cDNA was synthesized with Superscript
II reverse transcriptase (Invitrogen) primed by oligo-dT (Invitrogen). virus plasmid; and 1 g of pSV-JRFL env or pcVSV-G. Virus-con-
taining supernatant was harvested two days posttransfection andRodent (GenBank #BC003314) and human (GenBank #NM_021822)
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quantitated three days later using Luc-Lite Plus reagent (Packard) dation for AIDS Research, and Concerned Parents for AIDS Re-
search.and expressed as the average counts per second (cps). Data are
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